Table 1.
Clinical characteristics of the study subjects
| Atorvastatin (N = 11) | Combination (N = 10) | p | |
|---|---|---|---|
| Age, years | 58 (51, 64) | 57 (43, 63) | 0.75 |
| Male | 9 (82) | 9 (90) | 1.00 |
| Medical history | |||
| Hypertension | 8 (73) | 6 (60) | 0.88 |
| Diabetes mellitus | 2 (18) | 1 (10) | 1.00 |
| LDL-C ≥160 mg/dL | 4 (36) | 0 (0) | 0.12 |
| Smoking | 7 (64) | 6 (60) | 1.00 |
| Coronary artery disease | 6 (55) | 7 (70) | 0.78 |
| Body mass index, kg/m2 | 24.4 (23.4, 25.6) | 25.9 (23.4, 26.5) | 0.44 |
| Laboratory values, mg/dL | |||
| Total cholesterol | 214 (191, 261) | 200 (163, 211) | 0.17 |
| Triglyceride | 187 (125, 341) | 120 (105, 184) | 0.26 |
| HDL-C | 45 (42, 54) | 39 (37, 45) | 0.06 |
| LDL-C | 110 (95, 155) | 134 (102, 142) | 0.83 |
| Medications | |||
| Aspirin | 7 (64) | 7 (70) | 1.00 |
| β-blockers | 5 (46) | 4 (40) | 1.00 |
| Calcium channel blockers | 3 (27) | 3 (30) | 1.00 |
| RAS inhibitors | 6 (55) | 5 (50) | 1.00 |
Variables are expressed as median (25th percentile, 75th percentile) or number (%), HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, RAS renin-angiotensin system